Interferencia del levamisol y de los metabolitos de su degradación sobre los métodos de cuantificación de colesterol y triacilglicéridos séricos / Interference of levamisole and its degradation metabolites with the methods for quantitation of cholesterol and triacylglycerides

La posible interferencia del levamisol y de los productos de su degradación sobre los métodos de cuantificación de colesterol total y triacilglicéridos fue valorada y se observó la no existencia de efecto alguno a concentraciones de interés terapéutico sobre las técnicas que se evaluaron. Se concluyó que cualquier alteración encontrada en los valores de estas dos variables medidas por estos métodos en pacientes tratados con el fármaco, se debe a un efecto de la droga sobre el metabolismo de los lípidos y no a una interferencia de la misma con el método de ensayo.

Levamisole in experimentally-induced gastric ulcer: a comparative study

Different doses of levamisole [LVM], an antihelminthic and immunostimulant drug, were compared with some known, antipeptic ulcer agents regarding the protective effect against experimental gastric ulceration induced in rats by either indomethacin or stress. The reductions in the incidence of ulceration, ulcer score, ulcer index and the preventive index produced by LVM were very close to those produced by pirenzepine and cimetidine. The results produced by colloidal bismuth and sucralfate were inferior to those of LVM. On the gastric secretions, LVM significantly reduced the acid output, the acid concentration as well as the pepsin concentration and in addition, it significantly increased the mucus secretion. Such results were in good matching with those produced by cimetidine, were even better than those produced by pirenzepine and superior to those of colloidal bismuth and sucralfate